M2Gen
M2Gen is a Tampa-based health informatics company that operates the Zephyr AI multi-modal AI platform for biopharma and diagnostics partners, applying machine learning to large-scale real-world data to accelerate drug development and precision-medicine delivery via enterprise subscriptions.
- Company typePrivate
- Founded2006
- HeadquartersTampa, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What M2Gen does
M2Gen is a privately held health informatics company headquartered in Tampa, Florida, founded in 2006 and operating with 51–100 employees. Its commercial offering, surfaced under the Zephyr AI brand, is a multi-modal AI platform that applies state-of-the-art machine learning to enterprise-scale real-world data, transforming fragmented, multi-modal data into actionable insights for biopharma and diagnostics partners across the therapeutic lifecycle — from discovery and validation through clinical deployment.
The core platform uses interpretable machine learning models designed to integrate directly into partners' existing R&D and clinical workflows, with the explicit value proposition of avoiding new assays and accelerating drug development and precision-medicine delivery. AI modalities span structured and multi-modal data, and the platform is positioned to deliver insights at both population scale and patient-level precision.
M2Gen monetizes through enterprise B2B partnerships with biopharma and diagnostics companies under a 'Partner With Us' model, using annual subscription-style contracts with custom, quote-based pricing and direct enterprise field sales as the go-to-market motion. The company has been capitalized by Hearst Communications ($75M in 2017) and a 2021 strategic round led by CD&R with McKesson Ventures and Merck Global Health Innovation Fund, and is led by founder Bill Dalton, CEO Timothy Wright, and a full commercial and data C-suite.
M2Gen firmographics
Firmographics- Name
- M2Gen
- Legal name
- Zephyr AI
- Website
- https://m2gen.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- M2Gen is a Tampa-based health informatics company that operates the Zephyr AI multi-modal AI platform for biopharma and diagnostics partners, applying machine learning to large-scale real-world data to accelerate drug development and precision-medicine delivery via enterprise subscriptions.
- Ownership category
- akta.pro rank
M2Gen industry classification
Industry- Product category
- Precision Medicine AI Platform
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where M2Gen is headquartered
LocationHeadquarters
- HQ city
- Tampa
- HQ country
- United States
- HQ region
- North America
Markets served
M2Gen business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Biopharma Partnerships: Revenue generated through collaboration with biopharma companies to fine-tune multi-modal AI for drug development, seamlessly integrating into existing R&D workflows.
- Diagnostics Partnerships: Partnership revenue from diagnostics companies to develop and deploy precision medicine solutions that scale across clinical applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise partnership pricing - custom quotes |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
M2Gen product offering
Product offeringCore offering
M2Gen is a health informatics solutions company that applies state-of-the-art machine learning to large-scale, real-world data. Its multi-modal AI platform transforms fragmented data into actionable insights, supporting discovery, validation, and deployment across the therapeutic lifecycle. The company partners with biopharma and diagnostics firms to fine-tune AI models for new drugs and precision medicine solutions, integrating directly into existing R&D and clinical workflows without requiring new assays.
Product overview
Zephyr AI offers a unified multi-modal AI platform that applies state-of-the-art machine learning to large-scale, real-world data. The platform transforms fragmented, multi-modal data into actionable insights, designed to integrate directly into R&D and clinical workflows. The core Multi-Modal AI Platform drives discovery, validation, and deployment across the therapeutic lifecycle, helping biopharma and diagnostics partners reduce risk, accelerate development, and deliver precision medicine solutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Multi-Modal AI Platform A unified AI platform that applies state-of-the-art machine learning to large-scale, real-world data, transforming fragmented multi-modal data into actionable insights for drug discovery, validation, and clinical deployment. Designed to integrate directly into partners' R&D and clinical workflows without requiring new assays. Built for biopharma and diagnostics companies seeking to accelerate development timelines and reduce R&D risk.
Companies that use M2Gen
Customer profileSegments2 records
Ideal customer profiles2 records
M2Gen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
M2Gen partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Biopharma CompaniescoreZephyr AI collaborates with biopharma companies to fine-tune their multi-modal AI for drug development. The partnership involves integrating AI capabilities directly into existing R&D workflows without requiring new assays. The collaboration spans from discovery to clinical application, helping reduce risk and accelerate drug development timelines.
- Diagnostics CompaniescorePartnership with diagnostics companies to develop and deploy precision medicine solutions. The collaboration enables diagnostics companies to leverage Zephyr AI's multi-modal AI platform and enterprise-scale real-world data capabilities, integrating into existing clinical workflows to deliver precision medicine at scale.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
M2Gen competitors and assessment
Company assessmentDirect peers
- Tempus Labs: Tempus is a precision medicine AI company that applies machine learning to large-scale clinical and molecular real-world data for biopharma and diagnostics customers. It is the most direct peer to M2Gen, sharing both the multi-modal AI platform model and the biopharma/diagnostics enterprise GTM.
- Flatiron Health: Flatiron Health aggregates oncology real-world data and applies analytics for biopharma research and clinical decision support. It directly mirrors M2Gen's oncology real-world data and biopharma partnership model.
- ConcertAI: ConcertAI is a healthcare AI company focused on oncology real-world data and enterprise insights for biopharma and providers. Its oncology-centric, AI-driven real-world evidence model is highly comparable to M2Gen's precision-medicine platform.
- Owkin: Owkin applies federated AI/ML to multi-modal real-world patient data to accelerate drug discovery and development for biopharma. It overlaps M2Gen on multi-modal AI + real-world data + biopharma partnership GTM.
- Recursion Pharmaceuticals: Recursion is an AI/ML-driven drug discovery platform operating across the therapeutic lifecycle, combining large-scale data with machine learning to identify and develop new therapeutics. It competes for the same biopharma AI-discovery budgets.
- insitro: insitro is an AI-driven drug discovery company that combines machine learning with biological data to accelerate therapeutic development. It is an emerging direct peer in the AI-for-drug-discovery category.
Emerging players
- PathAI: PathAI applies AI/ML to pathology and diagnostics data, with biopharma partnerships for drug development. While pathology-focused, it competes for the same diagnostics-vertical AI/RWD budgets.
- GNS Healthcare: GNS Healthcare uses causal AI on patient data to inform drug development and precision medicine. It overlaps M2Gen on real-world data analytics and biopharma partnership revenue.
- Deep Genomics: Deep Genomics applies machine learning to RNA biology and genomic data for therapeutic discovery. It is an emerging player in the AI/ML-enabled drug discovery category adjacent to M2Gen's therapeutic-lifecycle positioning.
Broad incumbents
- IQVIA: IQVIA is a global life sciences services and data incumbent offering real-world evidence, AI analytics, and clinical research solutions to biopharma. It overlaps M2Gen's value chain at the enterprise scale, though as a broad portfolio incumbent rather than a focused AI-native platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
M2Gen social profiles
Digital presenceM2Gen financial estimates
Financial estimateRevenue estimate
Valuation estimate
M2Gen leadership team
Management profileNumber of profiles
Profiles8 records
M2Gen funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
M2Gen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about M2Gen
What does M2Gen do?
M2Gen is a health informatics solutions company that applies state-of-the-art machine learning to large-scale, real-world data. Its multi-modal AI platform transforms fragmented data into actionable insights, supporting discovery, validation, and deployment across the therapeutic lifecycle. The company partners with biopharma and diagnostics firms to fine-tune AI models for new drugs and precision medicine solutions, integrating directly into existing R&D and clinical workflows without requiring new assays.
Is M2Gen a public or private company?
M2Gen is a private company. It is classified as venture growth investor backed and is currently operating.
When was M2Gen founded?
M2Gen was founded in 2006. It employs 51 to 100 people.
Where is M2Gen based?
M2Gen is headquartered in Tampa, United States, in the North America region.
How does M2Gen make money?
Two revenue lines are on record. Biopharma Partnerships are the primary driver. The others are diagnostics Partnerships.
Who are M2Gen's main competitors?
Direct peers on record are Tempus Labs, Flatiron Health, ConcertAI, Owkin, Recursion Pharmaceuticals and insitro. Emerging players are PathAI, GNS Healthcare and Deep Genomics. IQVIA is listed as a broad incumbent.
Does M2Gen have an API?
No public API is recorded for M2Gen.
What industry is M2Gen in?
M2Gen's product category is Precision Medicine AI Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 5417 and its SIC code is 7373.